James M. Cornelius's most recent trade in MBX Biosciences Inc. was a trade of 16,000 Stock option (right to buy) done . Disclosure was reported to the exchange on June 5, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| MBX Biosciences Inc. | James M. Cornelius | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2025 | 16,000 | 16,000 | - | - | Stock option (right to buy) | |
| MBX Biosciences Inc. | James M. Cornelius | Director | 16 Sep 2024 | 994,069 | 0 | - | - | Series A Convertible Preferred Stock | ||
| MBX Biosciences Inc. | James M. Cornelius | Director | 16 Sep 2024 | 233,192 | 0 | - | - | Series B Convertible Preferred Stock | ||
| MBX Biosciences Inc. | James M. Cornelius | Director | 16 Sep 2024 | 102,082 | 102,082 | - | - | Common Stock | ||
| MBX Biosciences Inc. | James M. Cornelius | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Sep 2024 | 15,963 | 15,963 | - | - | Stock Option (Right to Buy) |